NPT520-337 / EVER Pharma - LARVOL DELTA

Novel Combination Therapy Using PI3Kinase Inhibition and Immune Based Therapy for the Treatment of Glioblastoma Multiforme (SNO 2022) - "Based on these observations, we examined the potential of a novel, small molecule PI3K inhibitor GCT.Glio.1 (NPT520-337), which was designed to cross the blood brain barrier, to increase the sensitivity of GBM to immune based therapies and radiation...In conclusion, these results indicate that GCT.Glio.1 may sensitize GBM to immune checkpoint inhibitor and/or radiation therapies. Based on our encouraging pre-clinical data and early results from pre-clinical pharmacology and safety studies, we anticipate filing a pre-Investigational New Drug application (pre-IND) as the next step toward our goal of a clinical trial using this combination therapy."

Combination therapy • IO biomarker • Brain Cancer • Glioblastoma • Immune Modulation • Inflammation • Oncology • Solid Tumor